Intraoperative anticoagulation management during cardiac transplantation: For a patient with heparin-induced thrombocytopenia and a left ventricular assist device

Texas Heart Institute Journal

Volumn 35, Issue 1, 2008, Pages 62-65

  Wadia, Yasmin ^a,b   Cooper Jr , John R ^a   Bracey, Arthur W ^a   Pinto, Katheleen ^a   Frazier, O H ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

Cardiopulmonary bypass; Heart transplantation; Heparin adverse effects; Left ventricular assist device; Platelet factor 4 immunology; Thrombocytopenia chemically induced

Indexed keywords

GLYCERYL TRINITRATE; HEPARIN; LEPIRUDIN; MILRINONE; PROTAMINE;

ADULT; ANAMNESIS; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; ASSISTED CIRCULATION; CARDIOMYOPATHY; CARDIOPULMONARY BYPASS; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART TRANSPLANTATION; HUMAN; LOADING DRUG DOSE; MALE; MEDICAL INSTRUMENTATION; PEROPERATIVE CARE; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; THROMBOCYTOPENIA; THROMBOSIS; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANTICOAGULANTS; CARDIOMYOPATHY, DILATED; CARDIOPULMONARY BYPASS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HEPARIN; HIRUDINS; HUMANS; INTRAOPERATIVE PERIOD; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 42549150757     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 1958;76(2):219-27.
2. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973;136(3):409-16.
3. Bell WR, Tomasulo PA, Alving BM, Duffy TP. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med 1976;85(2):155-60.
4. Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit 1983;5(2):205-11.
5. Powers PJ, Kelton JG, Carter CJ. Studies on the frequency of heparin-associated thrombocytopenia. Thromb Res 1984;33(4):439-43.
6. Chong BH. Heparin-induced thrombocytopenia. In: Michelson AD, editor. Platelets. 1st ed. New York: Academic Press; 2002. p. 571-91.
7. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993;305(4):208-15.
8. Leyvraz PF, Bachmann F, Hoek J, Buller HR, Postel M, Samama M, Vandenbroek MD. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin [published erratum appears in BMJ 1991;303(6812):1243]. BMJ 1991;303(6802):543-8.
9. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-5.
10. Kleinschmidt S, Seyfert UT. Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice. Angiology 1995;46(1):37-44.
11. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99(19):2530-6.
12. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101(4):653-5.
13. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery [corrected and republished in Ann Thorac Surg 2003;76(6):2121-31]. Ann Thorac Surg 2003;76(2):638-48.
14. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95(5):1242-6.
15. Koster A, Sanger S, Hansen R, Sodian R, Mertzlufft F, Harke C, et al. Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. ASAIO J 2000;46(3):319-22.
16. Frazier OH, Myers TJ, Gregoric ID, Khan T, Delgado R, Croitoru M, et al. Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation 2002;105(24):2855-60.
17. Siegenthaler MP, Martin J, van de Loo A, Doenst T, Bothe W, Beyersdorf F. Implantation of the permanent Jarvik-2000 left ventricular assist device: a single-center experience. J Am Coll Cardiol 2002;39(11):1764-72.
18. Kurup V, Transue S, Wu Y, Rinder HM, Barash P, Dewar M. Cardiac surgery in a patient with heparin-induced thrombocytopenia - cautions with use of the direct thrombin inhibitor, argatroban. Conn Med 2006;70(4):245-50.
19. Wasowicz M, Vegas A, Borger MA, Harwood S. Bivalirudin anticoagulation for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Can J Anaesth 2005;52(10):1093-8.
20. Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001;94(2):245-51.